Literature DB >> 19857765

Fulminant hepatic failure induced by venlafaxine and trazodone therapy: a case report.

O Detry1, J Delwaide, A De Roover, M F Hans, M H Delbouille, J Monard, P Honoré.   

Abstract

Although acute hepatitis may be a side effect of many medications, most cases are reversible after treatment interruption, and fulminant hepatic failure (FHF) is rare. Venlafaxine and trazodone are 2 popular antidepressant agents. Alteration of liver enzyme levels has been reported as a side effect of these drugs at normal doses. Herein we have reported the case of a 48-year-old woman without any previous history of liver disease, who developed fulminant liver failure after 4 months of venlafaxine and trazodone therapy. She required liver transplantation, a procedure that was successful with full patient recovery. The first 5 years of follow-up were uneventful. This case documented that venlafaxine and trazodone at normal doses can produce severe liver toxicity. Liver tests should be monitored regularly in patients who receive this therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19857765     DOI: 10.1016/j.transproceed.2009.09.022

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  8 in total

1.  Venlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal Dysfunction.

Authors:  Elham Ahmadian; Hossein Babaei; Alireza Mohajjel Nayebi; Aziz Eftekhari; Mohammad Ali Eghbal
Journal:  Adv Pharm Bull       Date:  2016-12-22

Review 2.  Gastrointestinal Dysfunction in Parkinson's Disease.

Authors:  Delaram Safarpour; Kaveh Sharzehi; Ronald F Pfeiffer
Journal:  Drugs       Date:  2022-01-25       Impact factor: 9.546

Review 3.  Pharmacokinetics of antidepressants in patients with hepatic impairment.

Authors:  Massimo Carlo Mauri; Alessio Fiorentini; Silvia Paletta; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 4.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

5.  Acute Liver Failure due to Trazodone and Diazepam.

Authors:  Sofia Carvalhana; Ana Oliveira; Pedro Ferreira; Margarida Resende; Rui Perdigoto; Eduardo Barroso
Journal:  GE Port J Gastroenterol       Date:  2016-11-16

Review 6.  Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity.

Authors:  Diogo Telles-Correia; António Barbosa; Helena Cortez-Pinto; Carlos Campos; Nuno B F Rocha; Sérgio Machado
Journal:  World J Gastrointest Pharmacol Ther       Date:  2017-02-06

Review 7.  Rediscovering trazodone for the treatment of major depressive disorder.

Authors:  Andrea Fagiolini; Alessandro Comandini; Mario Catena Dell'Osso; Siegfried Kasper
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

Review 8.  Antidepressants- and antipsychotics-induced hepatotoxicity.

Authors:  Nevena Todorović Vukotić; Jelena Đorđević; Snežana Pejić; Neda Đorđević; Snežana B Pajović
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.